Mostrar el registro sencillo del ítem
Neuroprotective effects of insulin-like growth factor II in a mouse model of Parkinson's disease
dc.contributor.author | Ladrón de Guevara-Miranda, David | |
dc.contributor.author | Martín-Montañez, Elisa | |
dc.contributor.author | Valverde, Nadia | |
dc.contributor.author | Lara, Estrella | |
dc.contributor.author | Romero-Zerbo, Silvana Yanina | |
dc.contributor.author | Millón-Peñuela, Carmelo | |
dc.contributor.author | Boraldi, Federica | |
dc.contributor.author | Ávila-Gámiz, Fabiola | |
dc.contributor.author | Pérez-Cano, Ana María | |
dc.contributor.author | Garrido-Gil, Pablo | |
dc.contributor.author | Labandeira-García, José Luis | |
dc.contributor.author | Santín-Núñez, Luis Javier | |
dc.contributor.author | Pavía-Molina, José | |
dc.contributor.author | García-Fernández, María Inmaculada | |
dc.date.accessioned | 2022-07-26T09:42:01Z | |
dc.date.available | 2022-07-26T09:42:01Z | |
dc.date.issued | 2022-07-20 | |
dc.identifier.uri | https://hdl.handle.net/10630/24781 | |
dc.description.abstract | Progressive degeneration of the nigrostriatal dopaminergic pathway is a core, currently irreversible pathological hallmark of Parkinson’s disease (PD) that leads to a variety of motor and non-motor symptoms. Here, we aimed to study the potential neuroprotective effects of insulin-like growth factor II (IGF-II) in a PD mouse model based on the chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and probenecid (MPTP/p), which induces loss of dopaminergic neurons in the Substantia Nigra pars compacta (SNc). Male C57BL6/J mice (N=36) received a 5-week treatment with MPTP/p (or vehicle) and were co-treated with chronic IGF-II (or saline) from either the beginning of the procedure (plus an additional week, days 1-44) or once the MPTP/p insult was already triggered (days 21-44). Baseline and post-treatment measurements for motor performance in the Rotarod and self-grooming in an Open Field were taken. Likewise, dopaminergic (TH, DAT) and neuroinflammatory-related (GFAP) markers in the SNc and the dorsal striatum were studied by immunohistochemistry. Our results revealed that both early and delayed IGF-II co-treatment were successful in preventing motor and behavioral impairment in the MPTP/p model. Moreover, chronic IGF-II protected against MPTP/p-induced loss of dopaminergic neurons in the SNc and promoted a significant recovery of dopaminergic activity in the terminals located in the dorsal striatum, further reducing reactive astrocytosis in these brain regions. Thus, we demonstrated the neuroprotective role of IGF-II in a mouse model of PD, highlighting its potential as a promising therapeutical target for treating this disease. Funding: UMA18-FEDERJA-004, PID2020-113806RB-I00. Universidad de Málaga, Campus de Excelencia Internacional Andalucía Tech. | es_ES |
dc.description.sponsorship | Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech. | es_ES |
dc.language.iso | eng | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Parkinson, Enfermedad de - Congresos | es_ES |
dc.subject | Medicamentos - Ensayos - Congresos | es_ES |
dc.subject | Medicamentos - Efectividad - Congresos | es_ES |
dc.subject | Experimentación animal - Congresos | es_ES |
dc.subject.other | Insulin-like growth factor II | es_ES |
dc.subject.other | Neuroprotection | es_ES |
dc.subject.other | Parkinson's disease | es_ES |
dc.title | Neuroprotective effects of insulin-like growth factor II in a mouse model of Parkinson's disease | es_ES |
dc.type | info:eu-repo/semantics/conferenceObject | es_ES |
dc.relation.eventtitle | IV International Congress of Psychobiology | es_ES |
dc.relation.eventplace | Valencia, España | es_ES |
dc.relation.eventdate | 20/07/2022 | es_ES |